The First Fluorescent Diboronic Acid Sensor Specific for Hepatocellular Carcinoma Cells Expressing Sialyl Lewis X[#]

Wenqian Yang,¹ Haiying Fan,² Xingming Gao,¹ Shouhai Gao,1 Vishnu Vardhan Reddy Karnati,1 Weijuan Ni,1 W. Borden Hooks,2 John Carson,2 Brent Weston,2,* and Binghe Wang1,* 1 Department of Chemistry Atlanta, Georgia 30303 of carcinogenicity [16]. Diagnosis and staging of HCC is often limited due to 2Department of Pediatrics

signed and synthesized a series of 26 diboronic acid carbohydrate structures. compounds as potential fluorescent sensors for such carbohydrates. Among these compounds, 7q was able to fluorescently label cells expressing high levels of Results and Discussion sLex (HEPG2) within a concentration range of 0.5 to 10 M. This compound (7q) did not label cells express- Chemistry For this project, we selected sLex (Figure 1) as our initial ing Lewis Y (HEP3B), nor cells without fucosylated antigens (COS7). This represents the first example of target for sensor design because it is implicated in the a fluorescent compound labeling cells based on cell development of liver and colon cancer [16, 19]. Critical surface carbohydrate structures. to the development of high affinity and high specificity

cell-surface biomarkers are useful diagnostics. Our lab- bind compounds with a diol structural motif with high oratory has been particularly interested in the develop- affinity [20]. By taking advantage of this strong interacment of fluorescent sensors for carbohydrates. It is tion, several molecular recognition systems for carboknown that cell-surface carbohydrates, as part of glyco- hydrates based on boronic acid moieties have been sylated proteins and lipids, often form characteristic developed [21–31]. Recently, our lab has undertaken signatures of different cell types [1, 2]. In particular, extensive studies of the interaction of boronic acid and certain cell surface carbohydrates, such as sialyl Lewis diols and achieved a much greater understanding of the X (sLex), sialyl Lewis a (sLea), Lewis X (Lex), and Lewis factors that influence this complexation process [32]. Y (Ley) (Figure 1), have been associated with the devel- Our group has also developed a new method of making opment and progression of many types of cancers [3–6], including hepatocellular carcinoma (HCC), one of the polymerization of boronic acid monomers [33, 34]. How-

ity to express α (1,3)-fucosylated carbohydrates, which tin-mediated cell adhesion and inflammatory responses sensor construction difficult.
[8. 9], Inflammatory cytokines can increase the meta-
In designing sensors for saccharides, it is essential **bolic activity and expression of several heavily glycosy- that binding also trigger a reporting event. It has been**

lated acute phase reactants in HCC [10–14], and some inflammatory molecules appear to be involved in the progression of HCC. Alpha-fetoprotein, for example, is heavily fucosylated in chronic hepatitis and HCC [15]. Normally differentiated hepatocytes do not express Georgia State University **SLEX, but chronically diseased liver expresses high lev-** state of the state of **33 Gilmer St. S.E. els of sLex, and this is associated with a high degree**

University of North Carolina inability to detect advanced disease. Treatment of HCC Chapel Hill, North Carolina 27599 is also impaired by lack of sensitive detection and further by drug resistance [17]. Biosensors that could both recognize occult metastasis and provide targeted delivery Summary of treatment could potentially improve chances for success in this disease. Herein, we describe our search for Carbohydrate antigens with subterminal fucosylation fluorescent diboronic acid compounds that can specifihave been implicated in the development and progres- cally recognize sLex [18]. One compound was able to sion of several cancers, including hepatocellular carci- fluorescently label HCC lines that express the target noma (HCC). Fluorescent sensors targeting fucosy- carbohydrate. This represents the first example of a lated carbohydrate antigens could potentially be used small organic molecule being used to fluorescently label for diagnostic and other applications. We have de- cells based on the specific recognition of cell-surface

sensors for carbohydrates is the need for recognition moieties that have strong interactions with the functional Introduction groups, such as hydroxyl groups, on a carbohydrate. It Fluorescent sensors capable of recognizing specific has been known since the 1940s that boronic acids can most common carcinomas worldwide [7]. ever, most of these early efforts were focused on mono-One specific example associated with the develop- saccharides. Effort in designing sensors for cell-surface ment and progression of human carcinomas is their abil- polysaccharides has been very limited [35]. Possible are important components of ligands involved in selec- rides and their conformational flexibility, which makes

In designing sensors for saccharides, it is essential [8, 9]. Inflammatory cytokines can increase the metaknown that anthracene fluorescence can be quenched by nitrogen lone pair electrons on an amino group (Fig- *Correspondence: bwwmd@med.unc.edu (Weston); wang@gsu.edu ure 2). However, this quenching can be removed or re- (Wang)

 $*$ A major part of this work was performed at North Carolina State **University, Department of Chemistry. bond formation [23, 36]. Since binding with a carbohy-**

Figure 1. Structures of Lewis Oligosaccharides

the boronic ester formation will also increase the B-N series of dicarboxylic acid linkers with different length, bond strength, which results in the masking of the nitro- rigidity, and spatial orientation in search of an optimal gen lone pair electrons. Consequently, the fluorescence arrangement. intensity of the anthracene system increases (Figure 2). The synthesis of these compounds is shown in Figure Several laboratories, including ours, have used this sys- 3. Starting from the readily available hydroxyaldehyde tem developed by the Shinkai group in the synthesis 1 [38], upon reductive amination with methylamine in of boronic acid-based fluorescent sensors, for mostly MeOH/THF and NaBH4, amine 2 was obtained in 90% monosaccharides [23–25, 37]. In this project, we also yield. The Boc-protected compound 3 was obtained in chose to use the Shinkai system as the reporter moiety 78% yield by treatment of 2 with di-*tert***-butyldicarbofor the synthesis of diboronic compounds as potential nate [(Boc)2O] in MeOH in the presence of triethylamine sensors for sLex. (TEA). This was followed by oxidation with pyridine sulfur**

we envisioned that diboronic acid compounds with the TEA to give aldehyde 4 in quantitative yield. The resulting proper spatial arrangement of the two boronic acid moi- aldehyde 4 was then converted to amine compound 5 eties, which are complementary to the multiple pairs of in 83% yield through reductive amination. Amine 5 was diols, have the potential for highly specific recognition coupled with various diacids using 1-(2-dimethylaminoof the target carbohydrate. Such a concept has been propyl)-3-ethylcarbodiimide hydrochloride (EDC) as the demonstrated several times in the preparation of diboro- activating reagent to furnish compounds 6 in 30–90% nic acid sensors for glucose and other monosaccharides yields. After deprotection of compounds 6 with trifluoro- [23–25, 37]. In this project, we chose to use a spacer acetic acid (TFA), the unprotected free amines were to link, through amide bond formation, two fluorescent then reacted with boronate 8 [23] in the presence of

tron Transfer System for these diboronic acids is shown in Figure 4. It can be

drate is known to increase the acidity of boronic acid, tial sensors (7, Figure 3). In doing so, we sampled a

For the construction of fluorescent sensors for sLex, trioxide in dimethylsulfoxide (DMSO) in the presence of boronic acid compounds for the synthesis of the poten- potassium carbonate to give the diboronic acids 7 (Table 1) in 30%–80% yields.

These compounds are designed to show significant fluorescence intensity changes upon binding with a complementary carbohydrate. In screening for their binding with the target carbohydrate, sLex, the fluorescence intensity changes of the sensor solutions upon addition of the carbohydrate were determined. Such experiments were conducted in a mixture of methanol and 0.1 M phosphate buffer (pH 7.4) (1:1, v/v). Methanol was used to improve the solubility of the sensor compounds. The sensor (7) concentration was fixed at 1 \times 10^{-5} or 1×10^{-6} M, and the concentration of sLex was **Figure 2. Illustration of the Anthracene-Based Photoinduced Elec- set at 60 M. The fluorescence intensity change profile**

Figure 3. Dibronic Acid Synthesis

(a) i. MeOH, THF, MeNH2 (40%, wt), ii. NaBH4, 90%; (b) MeOH, TEA, (Boc)2O, 78%; (c) DMSO, TEA, Py•SO3, 100%; (d) i. MeOH, THF, $MeNH₂$ (40%, wt), ii. NaBH₄, 83%. (e) CH₂Cl₂, EDC, HOOCRCOOH, **30–90%; (f) i. TFA, CH2Cl2, ii. CH3CN, 8, K2CO3, 30–80%.**

seen that these compounds showed varying degrees of fluorescence intensity changes upon addition of sLex, indicating varying degrees of affinity for the carbohydrate. Among them, compound 7q showed the greatest has been well described [16, 39]. These observations

drate antigens associated with the development of can- for sLex in transformation and progression to HCC are, cer. Overexpression of sLex in chronic inflammatory dis- however, not well understood. Biosensors that could eases of the liver has been reported in several contexts sensitively trace this development in vivo would likely by multiple investigators [15, 16, 39, 40]. Current evi- further our understanding of hepatocarcinogenesis, in dence in our laboratory suggests that sLex serves as a addition to providing new diagnostic and therapeutic marker for hepatocyte damage and regeneration, and approaches. its expression is likely controlled by hepatic cytokines After demonstration of binding of the sensors to sLex operating in autocrine loops [10–14]. Similarly, Lewis Y in solution, it was desirable to see whether 7q, the comappears to be a sensitive marker for damaged intrahe- pound that showed the most significant fluorescence patic bile ducts [40, 41], but its role in the inflammatory intensity increase upon addition of sLex, could bind the process is much less evident. Loss and gain of sLex biomarker sLex on cell surfaces [19, 42]. We therefore

have been linked to the development of cirrhosis, a **frequent precursor of HCC. Such findings are compara-Biology ble to chronic inflammatory states preceding develop- ble to chronic inflammatory states preceding develop-Again, our rationale for sensor design targets carbohy- ment of colon carcinoma [8]. The specific role(s), if any,**

expression in variously differentiated HCC specimens chose a cell line that selectively expresses sLex on the

Figure 4. The Fluorescence Intensity Changes of the Diboronic Acids 7a-z upon Binding with sLex Sensor concentrations: 1×10^{-5} or 1×10^{-6} M. sLex concentration: 6×10^{-5} M; $\lambda_{ex} = 370$ nm, $\lambda_{em} = 426$ nm.

the sensor for cell surface sLex, HEP3B and COS7 cells ferent monoclonal antibodies directed at sLex, HEPG2 were labeled in parallel. COS7 expresses none of the cells were found to express high levels, while HEP3B fucosylated antigens associated with carcinoma pro- cells expressed little or none (Figure 5). Anti-Lewis Y gression and HEP3B expresses only the Lewis Y antigen monoclonal antibodies revealed the converse: high ex- [43, 44]. Flow cytometry analysis of HCC lines with anti- pression on HEP3B and little or no staining of HEPG2. carbohydrate monoclonal antibodies was performed to None of the cell lines expressed Lewis X or sialyl Lewis

jected to flow cytometric analysis as described in experimental pro- studies using fluorimetry. cedures. Anti-CD18 results are presented as negative controls. Images from a representative cell-labeling experiment

Monoclonal antibodies CSLEX-1 and KM93 both recognize sLex.

Data presented here are the representative tion of HEPG2 and HEP3B cells was gated at 1.5×10^1 units, and over 95% of stained cells were identified by these procedures with **each primary antibody used. As expected, compound 7q labeled only HEPG2 cells,**

surface, HEPG2 (Figure 5). To examine the selectivity of characterize surface glycan expression. Using two dif**a, related antigens expressed on other forms of carcinoma [9, 19, 42]. These cell lines were then used for the fluorescent labeling studies with the sensors.**

HEPG2 and control cell lines were incubated with compound 7q and three other diboronic acids (7b, 7d, 7y) selected as controls, examined under fluorescent microscopy, and photographed. Images were subjected to densitometry measurement as described in Experimental Procedures. As seen with sLex solution binding studies summarized in Figure 4, Compound 7q was highest in mean gray value when binding HEPG2 cells expressing sLex (Figure 6). Compound 7q did not recognize Lewis Y on HEP3B cells. Compound 7b avidly bound Lewis Y-expressing HEP3B cells, which correlates with solution binding studies using 7b and Lewis Y (data not shown). Compound 7b did not recognize sLex on HEPG2 cells at this concentration (1 μ **M), again correlating with solution binding studies (Figure 4). Even at this relatively low concentration, compound 7y recognized surface sLex and Lewis Y with equal avidity, concordant with solution binding studies (data not shown). Compound 7d, which had low affinity for both sLex and Lewis Y in solution, did not label HEPG2 or HEP3B. None Figure 5. Flow Cytometry Analysis of Surface Antigens on HEPG2, of the compounds bound to COS7 cells at any of the HEP3B, and COS7 Cells concentrations tested. The above results showed that Cells were harvested, stained with monoclonal antibodies, and sub- the cell labeling matched well with the solution binding**

described in Experimental Procedures. One well was incubated only
in methanol/PBS without compound as a negative control ("neq"). **Mean gray values (***y* **axis) were determined after subtraction of cell- to Ley-expressing cells (HEP3B). This will serve as an**

We also examined the selectivity of sensor 7b. Com**pound 7b bound Lewis Y-expressing HEP3B cells at all concentrations tested (0.5–10 M). At higher concentra- Significance tions, 7b also labeled HEPG2 cells, suggesting crossreactivity with sLex (e.g., 5 M, Figure 7). Thus, sensor Our laboratory has a long-standing interest in the de-7q alone appears to have both high sensitivity and speci- velopment of small molecule sensors for various anaficity for sLex when compared to related compounds lytes. Such sensors can be used for diagnostic purand carbohydrate antigens. poses. They can also be considered antibody mimics**

essential for binding, HEPG2 cells (sLex-expressing) Antibodies have been used for the development of were treated with neuraminidases specific for (2,3) in vitro diagnostic and detection tools, targeted drug sialic acid linkages (MDL number MFCD01092203, delivery vectors, and tissue-specific imaging agents. SIGMA #N7271) and (2,3)/ (2,6) sialic acid residues However, success in the in vivo application of anti- (MDL number MFCD01092201, SIGMA #N5521). Both body-based diagnostic and therapeutic agents has neuraminidases consistently reduced binding of 7q by been limited partly because of their poor stability, im-50%–75% (e.g.; mean gray value of control 69.8 4; munogenecity, poor permeability, and complexity in

ments), indicating that sialic acid is required for binding of 7q. To examine the role of the fucose moiety in 7q binding, HEPG2 were also incubated with fucosidase recognizing α (1,3)- and (1,4) –linked fucose (MDL num**ber MFCD00130491, SIGMA #F3023). This specific fucosidase reduced 7q binding by 50%–75% (mean gray** value 23.5 ± 11 , $n = 8$ experiments). Fucosidases re**cognizing other linkages (e.g.; 1,6, MDL number MFCD01092200, SIGMA #F6272; 1,2, MDL number MFCD01092199, SIGMA #F9272) had no significant effect on 7q binding (data not shown). Incubation with both (1,3/1,4)fucosidase and (2,3)neuraminidase (same buffers and conditions except pH 5.5) showed almost complete inhibition of 7q binding (mean gray value less** than 10 ± 2 for N7271/F3023-treated cells, $n = 4$ experi**ments). Taken together, these results indicate that 7q likely requires both fucose and sialic acid residues when**
 Binding to HCC and Control Cell Line
 Cells ware labeled with 1 w.M of concers 7b, 7d, 7y, and 7g as and it is fortuitous that among this first group of dibor

It is fortuitous that among this first group of diboronic Cells were labeled with 1 M of sensors 7b, 7d, 7y, and 7q as at low concentrations (0.5 μ **M) without cross-reactivity** excellent lead compound for further structural optimiza**tions. However, much more work is needed to truly un**exhibiting dose-responsive fluorescence over the range derstand the structural features of 7q that led to this
of 0.5–10 μ M. Even at higher concentrations, (e.g., 5 μ M, specific labeling activity. Such work will inv

To examine whether all components of sLex were for the high-specificity recognition of cell biomarkers. mean gray value of N7271-treated 25 9, n 8 experi- chemical conjugation with the diagnostic or imaging

> **Figure 7. Representative Fluorescent Labeling Studies of HEPG2, HEP3B, and COS7 Cells**

> **HEPG2 cells express only sLex, HEP3B cells express only Lewis Y, and COS7 cells do not express either antigen. Compounds 7q (S-23)** and **7b** (S-3) are used at 5μ M in the examples **shown. Excitation wavelength 370 nm and emission wavelength 426 nm. Scale in** lower right corner indicates 10 μ m length.

agents. Small organic molecule-based compounds *(10-Formyl-anthracen-9-ylmethyl)-methyl-carbamic acid* capable of specific recognition of cell-surface bio-
markers can be considered antibody mimics and can
be used for the same type of applications. However,
be used for the same type of applications. However,
prepared was a **the small organic molecule antibody mimics have the 45.9 mmol) dissolved in dry DMSO (20 mL) over a period of 30 min. advantage of having more desirable pharmaceutical, The reaction mixture was stirred at room temperature under nitrogen for 30 min, and then poured into ice-water (300 mL), extracted with**
biopharmaceutical, and chemical properties for the ethyl acetate (3 × 100 mL), dried over MgSO₄. Solvent evaporation **development of pharmaceutical agents. The fluorescent sensor described in this paper represents the** $\frac{1}{N}$ NMR (CDCl₃) $\frac{3}{8}$ 11.51 (s, 1H), 8.90 (d, *J* = 8.5 Hz, 2H), 8.51 (d, *J* = 1.51 (d, *J* = 1 **rescently label cells based on the cell-surface carbo-** *Methyl-(10-methylaminomethyl-anthracen-9-ylmethyl)* **hydrate structures. Further development along this** *carbamic acid tert-butyl ester (5)* line could lead to a number of small molecule antibody
mimics that can be used for labeling, drug delivery,
and MeOH (50 mL). To this solution was added the
autosocition of methylamine (40%, wt, 20 mL)
and MeOH (50 mL). T

83%). All ¹ H and 13C NMR spectra were recorded at 300 MHz and 75 MHz, ¹ (s, 2H), 4.71 (s, 2H), 2.69 (s, 3H), 2.46 (s, 3H), 1.55 (s, 9H). respectively, with tetramethylsilane as the internal standard. Column 13C NMR R chromatography was performed using silica gel (200-400 mesh) from Aldrich and neutral activated Brockmann I aluminum oxide (~150 79.7, 47.8, 42.6, 36.9, 31.6, 28.6. IR (cm⁻¹): 1686. HRMS (FAB) calcu-
mesh) from FM Science. Flemental analyses were performed by lated for C₂₃H₂₈N₂O mesh) from EM Science. Elemental analyses were performed by **Atlantic Microlab, Inc., Norcross, GA. Mass spectral analyses were sis calculated for C23H28N2O2: C, 75.79; H, 7.74; N, 7.69. Found: C,** performed by the North Carolina State University Mass Spectro-**1999 1201**, 16, 171; N, 7.53.
metry Facility and the University of Kansas Mass Spectrometry
metry Facility and the University of Kansas Mass Spectrometry metry Facility and the University of Kansas Mass Spectrometry **General Procedures for Procedures for Protected**
Laboration in a protective assessed the Protected Contract CO contract **Diamines (6)** Laboratory. IR spectra were recorded on a Perkin-Elmer 1600 series
spectrometer. Tetrahydrofuran (THF) was distilled from Na and
benzophenone. Acetonitrile (CH₃CN) and dichloromethane (CH₂Cl₂)
were distilled from Ca

temperature under nitrogen for 16 hr and then sodium borohydride *undecanoyl]-methyl-amino}-methyl)-anthracen-9-* **(0.90 g, 23.7 mmol) was added and the mixture stirred for another** *ylmethyl]-methyl-carbamic acid tert-butyl ester (6a)* **30 min. After solvent evaporation, the resulting solid was dissolved in the mixture of ethyl acetate (100 mL) and water (50 mL). The in the mixture of ethyl acetate (100 mL) and water (50 mL). The 7.59–7.54 (m, 8H), 5.71 (s, 4H), 5.54 (s, 4H), 2.60 (s, 6H), 2.49 (s, 6H), organic phase was separated and dried over MgSO4. Solvent evapo- 2.40–2.35 (m, 4H), 1.72–1.55 (m, 22H), 1.36–1.31 (m, 12H). IR (cm¹): ration gave a crude product, which was purified on a silica gel** 1684 **, 1637. HRMS (FAB) calculated for** $C_{58}H_{75}N_4O_6$ **(M⁺ + H) column, eluting with MeOH/CH2Cl2 (1/50), to give compound 2 as a 923.5687, found 923.5716. yellow solid (1.91 g, 90%). ¹H NMR (CDCI₃)** δ **8.45-8.42 (m, 2H). 8.37–8.34 (m, 2H), 7.55–7.52 (m, 4H), 5.64 (s, 2H), 4.65 (s, 2H), 2.65** *methyl]-anthracen-9-ylmethyl}-methyl-carbamoyl)-* **(s, 3H).** *methyl]-phenyl-acetyl)-methyl-amino]-methyl}-anthracen-* **13C NMR (CDCl3) 133.4, 131.7, 130.4, 130.3, 126.2, 126.1, 125.1, 124.8, 57.7, 48.2, 37.3. HRMS (FAB) calculated for C** *9-ylmethyl)-methyl-carbamic acid tert-butyl ester (6b)* **17H18NO** (M⁺ + H) 252.1388, found 252.1373. Elemental analysis calculated for Yield 88%. ¹H NMR (CDCl₃) δ 8.47–8.39 (m, 8H), 7.53–7.49 (m, 8H), 2.62
C₂₂H₁₂NO: C, 81.24: H, 6.82: N, 5.57, Found: C, 80.96: H, 6.86: N, 5. **C 7.26 (d,** *J* **4.2 Hz, 4H), 5.74 (s, 4H), 5.53 (s, 4H), 3.81 (s, 4H), 2.62 17H17NO: C, 81.24; H, 6.82; N, 5.57. Found: C, 80.96; H, 6.86; N, 5.53. (s, 6H), 2.45 (s, 6H), 1.56 (s, 18H). IR (cm¹): 1684, 1643. HRMS (FAB)** *(10-Hydroxymethyl-anthracen-9-ylmethyl)-methyl-carbamic*

Compound 2 (2.10 g, 8.37 mmol), di-tert-butyl dicarbonate (3.80 g,
17.4 mmol), and trimethylamine (20 mL) were mixed in MeOH (120
mL) and then stirred at room temperature for 30 min. After removal
of the solvent, the resu $\frac{100 \text{ mL}}{100 \text{ mL}}$, washed with water (3 \times 50 mL), 10% aqueous solution of *tert-butyl ester (6c)*
 $\frac{100 \text{ mL}}{100 \text{ mL}}$, washed with water (3 \times 50 mL), 10% aqueous solution of Yield 44%. ¹H NMR (CDCl socium carbonate (50 mL), and saturated prime (50 mL) and dried
over MgSO₄. Solvent evaporation gave a crude product, which was
purified on a silica gel column, eluting with ethyl acetate/hexanes
purified on a silica ge purified on a silica gel column, eluting with ethyl acetate/nexanes
(1/50–1/2), giving compound 3 as a yellow solid (2.30 g, 78%). ¹H and assume and cludated for C₅₆H₆₃N₄O₈ (M⁺ + H) 919.4646, found **H 919.4681. Hz, 2H), 5.50 (s, 2H), 2.47 (s, 3H), 1.55 (s, 9H). 13C NMR (CDCl3)** *methyl]-anthracen-9-ylmethyl}-methyl-carbamoyl)-* **57.6, 42.7, 31.8, 28.7. IR (cm¹ for C22H25NO3 (M) 351.1834, found 351.1835. Elemental analysis** *tert-butyl ester (6d)* **calculated for C22H25NO3: C, 75.19; H, 7.17; N, 3.99. Found: C, 75.21; Yield 73%. ¹**

gave a yellow solid (2.30 g, 100%) without further purification. ¹H **first example of a small organic molecule used to fluo- 8.5 Hz, 2H), 7.70–7.61 (m, 4H), 5.56 (s, 2H), 2.48 (s, 3H), 1.56 (s, 9H).**

mixture was stirred at room temperature under nitrogen for 12 hr. **Sodium borohydride (1.00 g, 26.3 mmol) was added, and stirred for 30 min. After removal of the solvent in vacuo, the resulting residue Experimental Procedures was dissolved in ethyl acetate (100 mL), washed with water (3** \times **50 mL), and dried over MgSO4. Solvent evaporation gave a crude Chemistry product, which was purified on a silica gel column, eluting with General General General General MeOH/CH₂Cl₂** (1/2), giving compound 5 as a yellow solid (2.00 g, **H NMR (CDCl3) 8.44–8.39 (m, 4H), 7.56–7.53 (m, 4H), 5.51**

inder nitrogen for 12 hr, then washed with water $(2 \times 30 \text{ mL})$
ies. The excitation wavelength was set at 370 nm.

(10-Methylaminomethyl-anthracen-9-yl)-methanol (2)

To the solution of compound 1 (2.00 g, 8.47 mmol) in M

H NMR (CDCl3) 8.49–8.46 (m, 4H), 8.40–8.37 (m, 4H),

H NMR (CDCl3) 8.45–8.42 (m, 2H), *(10-{[(2-{2-[({10-[(Tert-Butoxycarbonyl-methyl-amino)-* Yield 88%. ¹H NMR (CDCI₃) δ 8.47-8.39 (m, 8H), 7.53-7.49 (m, 8H), (10-Hydroxymethyl-anthracen-9-ylmethyl)-methyl-carbamic (s, 6H), 2.45 (s, 6H), 1.56 (s, 18H). IR (cm⁻¹): 1684, 1643. HRMS (

acid tert-butyl ester (3)

Compound 2 (2 10 g 8.37 mmol), di-tert-butyl dicarbonate (3.80 g 10-

NMR (CDCl3) 8.51–8.43 (m, 4H), 7.60–7.55 (m, 4H), 5.71 (d, *J* **5.6** *(10-{[(3-{4-[2-({10-[(Tert-Butoxycarbonyl-methyl-amino)-* **156.0, 132.6, 131.3, 130.2, 129.9, 126.1, 125.8, 125.4, 125.0, 80.1,** *ethyl]-phenyl}-propionyl)-methyl-amino]-methyl}-* **): 3413, 1681. HRMS (FAB) calculated** *anthracen-9-ylmethyl)-methyl-carbamic acid*

H NMR (CDCl3) 8.48–8.45 (m, 4H), 8.38–8.35 (m, 4H), H, 7.27; N, 3.97. 7.57–7.54 (m, 8H), 7.18 (s, 4H), 5.71 (s, 4H), 5.53 (s, 4H), 3.06 (t, *J*

8.7 Hz, 4H), 2.65 (t, *J* **8.7 Hz, 4H), 2.53 (s, 6H), 2.48 (s, 6H), 1.56 (s, 2H), 2.65 (s, 3H), 2.62 (s, 3H), 2.53 (s, 3H), 2.49 (s, 3H), 1.58 (s, (s, 18H). IR (cm¹): 1684, 1643. HRMS (FAB) calculated for C58H67N4O6 18H). IR (cm¹**

anthracen-9-ylmethyl}-methyl-carbamoyl)-butyryl]- **7.50; N, 5.35.**

Yield 53%. ¹H NMR (CDCl₃) δ 8.48-8.45 (m, 4H), 8.39-8.35 (m, 4H), **7.55–7.52 (m, 8H), 5.69 (s, 4H), 5.54 (s, 4H), 2.63 (s, 6H), 2.54 (t,** *J methyl-carbamic acid tert-butyl ester (6m)* **7.0 Hz, 4H), 2.48 (s, 6H), 2.20–2.10 (m, 2H), 1.57 (s, 18H). IR (cm¹**

Yield 64%. 'H NMR (CDCl₃) δ 8.58–8.51 (m, 8H), 7.67–7.60 (m, 8H), and according the methyl-antino-methyl-antino-methyl-antino-methyl-antino-methyl-antino-methyl-antino-methyl-antino-methyl-antino-methyl-antino-methyl-an **H** NMR (CDCl₃) δ 8.54–8.20 (m, 8H), 7.64–7.44 (m, 8H), 854–8.20 (m, 8H), 7.64–7.44 (m, 8H), 854–8.20 (m, 8H), 7.64–7.44 (m, 8H), 854–8.20 (m, 8H), 7.64–7.44 (m, 8H), 859.4445, found 859.4445, found 859.445, found 859

found 935.4770. Elemental analysis calculated. for C60H62N4O6· *[10-({[5-({10-[(Tert-Butoxycarbonyl-methyl-amino)-methyl] enoyl]-methyl-amino}-methyl)-anthracen-9-ylmethyl]- [10-({[4'-({10-[(Tert-Butoxycarbonyl-methyl-amino)-methyl]-*

Yield 31%. ¹ H NMR (CDCl *carbonyl]-methyl-amino}-methyl)-anthracen-9-ylmethyl]-* **3) 8.46–8.43 (m, 4H), 8.36–8.32 (m, 4H), 7.59–7.56 (m, 8H), 5.79 (s, 2H), 5.68 (s, 4H), 5.52 (s, 4H), 3.24 (s, 4H),** *methyl-carbamic acid tert-butyl ester (6o)* **Yield 62%. 2.56 (s, 6H), 2.48 (s, 6H), 1.56 (s, 18H). IR (cm ¹): 1689, 1642. HRMS** 2.56 (s, 6H), 2.48 (s, 6H), 1.56 (s, 18H). IR (cm⁻¹): 1689, 1642. HRMS Yield 62%. ¹H NMR (CDCl₃) 8 8.40–8.20 (m, 8H), 7.80–7.40 (m, 16H), 1.
(FAB) calculated for C_{s2}H_{el}N₄O_s (M⁺ + H) 837.4591, found 837.4592 **(FAB)** calculated for C_{s2}H₆₁N₄O₆ (M⁺ + H) 837.4591, found 837.4592. 5.90 (s, 4H), 5.57 (s, 4H), 2.60 (s, 6H), 2.52 (s, 6H), 1.58 (s, 18H).
Elemental analysis calculated for C_{s2}H₆₀N₄O₆·2 H₂O: C, 71.55;

[10-({[3-({10-[(Tert-Butoxycarbonyl-methyl-amino)-methyl]- **76.32; H, 6.72; N, 5.93. Found: C, 76.29; H, 6.68; N, 5.94.** *anthracen-9-ylmethyl}-methyl-carbamoyl)-propionyl]- [10-({[6-({10-[(Tert-Butoxycarbonyl-methyl-amino)-methyl] methyl-amino}-methyl)-anthracen-9-ylmethyl]-methyl- anthracen-9-ylmethyl}-methyl-carbamoyl)-hexanoyl]-*

Yield 78%. ¹H NMR (CDCI₃) δ 8.48-8.41 (m, 8H), 7.60-7.55 (m, 8H), Yield 78%. 'H NMH (CDCl₃) 8 8.48–8.41 (m, 8H), 7.60–7.55 (m, 8H), carbamic acid tert-butyl ester (6p)
5.77 (s, 4H), 5.56 (s, 4H), 2.86 (s, 4H), 2.79 (s, 6H), 2.50 (s, 6H), 1.53 Yield 56%. 'H NMR (CDCl₃) 8 8.52–8.36 (m, \mathbf{H} (s, 18H). IR (cm⁻¹): 1685, 1643. HRMS (FAB) calculated for $\mathbf{C}_{50}H_{59}N_4O_6$ **(M**⁺ + H) 811.4356, found 811.4412. Elemental analysis calculated
 Hz, 4H), 1.90–1.20 (m, 6H), 1.90–1.20 (m, 6H), 1.90–1.20 (m, 6H), 1.90–1.20 (m, 6H), 1.57 (s, 18H). IR (cm⁻¹): 1683, 1635. IRMS
 HAR) calculated f

5.71 (s, 4H), 5.54 (s, 4H), 2.60 (s, 6H), 2.50 (s, 6H), 2.39 (t, *J* **1.5 7.40 (s, 4H), 5.86 (s, 4H), 5.55 (s, 4H), 2.51 (s, 12H), 1.62 (s, 18H). IR Hz, 4H), 1.90–1.40 (m, 8H), 1.58 (s, 18H). IR (cm⁻¹): 1684, 1636. HRMS (cm⁻¹): 1684, 1635. HRMS
(FAB) calculated for C_{tr}.H_rN.O. (M⁺ + H) 867 4982 found 867 5229 859.4435: found 859.4451. 859.4435; found 859.4451. (FAB) calculated for C54H69N4O6 (M H) 867.4982, found 867.5229.**

methyl]-anthracen-9-ylmethyl}-methyl-carbamoyl)- methyl]-anthracen-9-ylmethyl}-methyl-carbamoyl) ylmethyl]-methyl-carbamic acid tert-butyl ester (6j) ylmethyl}-methyl-carbamic acid tert-butyl ester (6r)

Yield 64%. ¹ H NMR (CDCl3) 8.49–8.38 (m, 8H), 7.59–7.56 (m, 8H), Yield 79%. ¹ 1.90–1.20 (m, 54H). IR (cm¹ $f_{\text{on}}C_{68}H_{95}N_4O_6$ (M⁺ + H), 1063.7173, found 1063.5746. Elemental calculated for $C_{60}H_{65}N_4O_7$ (M⁺ + H) 951.4697; found 951.4684.
analysis calculated for $C_{54}H_{58}N_4O_6$ ·0.5H₂O: C, 72.15; H, 8.92; N, **analysis calculated for C54H58N4O6·0.5H2O: C, 72.15; H, 8.92; N, 5.22.** *[10-({[4-({10-[(Tert-Butoxycarbonyl-methyl-amino)-methyl]-*

Found: C, /6.15; H, 8.92; N, 4./6.

10-{{[3-{{10-{[Tert-Butoxycarbonyl-methyl-amino}-methyl}-

anthracen-9-ylmethyl-methyl-amino}-methyl-aminop-methyl-aminop-methyl)-anthracen-9-

anthracen-9-ylmethyl-aminop-methyl-aminop-

H NMR (CDCl3) 8.52–8.45 (m, 8H), 7.60–7.56 (m, 8H), 1.90–1.86 (m, 4H), 1.77–1.50 (m, 4H), 1.55 (s, 18H). IR (cm¹ 1.90–1.86 (m, 4H), 1.55 (s, 18H), 5.58 (s, 4H), 2.53 (s, 12H), 1.59 (s, 1.90–1.86 (m, 4H), 1.77–1.50 (m, 4H), 1.55 (s, 18H). IR (cm⁻¹): 1682, 1.59 (s, 18H). IR (cm⁻¹): 1682, 1.59 (s, 18H). IR (cm⁻¹): 1688, 16994;
18 $(0.4 + 0.4)$ $(0.4 + 0.4)$ $(0.4 + 0.4)$ $(0.4 + 0.4)$ $(0.4 + 0.4)$ $(0.4 + 0.4)$ $(0.4 + 0.4)$ $(0.4 + 0.4)$ $(0.4 + 0.4)$ $(0.4 + 0.4)$ $(0.4 + 0.4)$ $(0.4 + 0.4)$ $(0.4 + 0.4)$ $(0.4 + 0.4)$ $(0.4 + 0.4)$ $(0.4 + 0.4)$ $(0.4 + 0.4)$ **H, 6.93; N, 6.05.** *anthracen-9-ylmethyl}-methyl-carbamoyl)-*

cyclohexanecarbonyl]-methyl-amino}-methyl)-anthracen-9- {10-[({4-[({10-[(Isopropoxycarbonyl-methyl-amino)-methyl] anthracen-9-ylmethyl}-methyl-carbamoyl)-methoxy]- ylmethyl]-methyl-carbamic acid tert-butyl ester (6t) **Yield 83%.** *benzoyl}-methyl-amino)-methyl]-anthracen-9-ylmethyl}-* **¹**

6.99–6.96 (m, 2H), 5.86 (s, 2H), 5.72 (s, 2H), 5.58–5.54 (m, 4H), 4.79 calculated for C54H65N4O6 (M H) 865.4904; found 865.4886.

18H). IR (cm⁻¹): 1682, 1626. HRMS (FAB) calculated for C₅₅H₆₁N₄O₇ **(M⁺ + H) 915.5061 found 915.5070. (M⁺ + H) 889.4462, found 889.4086. Elemental analysis calculated**
 (10-{{[4-{{10-{[Tert-Butoxycarbonyl-methyl-amino)-methyl]- for C₅₉H₆₀N₄O₇·H₂O: C, 73.56; H, 6.85; N, *[10-({[4-({10-[(Tert-Butoxycarbonyl-methyl-amino)-methyl]-* **for C52H60N4O7·H2O: C, 73.56; H, 6.85; N, 6.23. Found: C, 73.31; H,**

methyl-amino}-methyl)-anthracen-9-ylmethyl]-methyl- [10-({[13-({10-[(Tert-Butoxycarbonyl-methyl-amino) carbamic acid tert-butyl ester (6e) methyl]-anthracen-9-ylmethyl}-methyl-carbamoyl)- **H NMR (CDCl3) 8.48–8.45 (m, 4H), 8.39–8.35 (m, 4H),** *tridecanoyl]-methyl-amino}-methyl)-anthracen-9-ylmethyl]-*

): Yield 52%. ¹ 7.0 Hz, 4H), 2.46 (s, 6H), 2.20–2.10 (lfl, 2H), 1.37 (s, 16H). IR (CIT) $\frac{1}{168}$, 191 (Sexter) $\frac{1}{168}$, 191 (S

methyl-amino}-methyl)-anthracen-9-ylmethyl]-methyl-

carbamic acid tert-butyl ester (6f)

Yield 64%. ¹H NMR (CDCl_s) δ 8.58–8.51 (m, 8H), 7.67–7.60 (m, 8H),

Yield 64%. ¹H NMR (CDCl_s) δ 8.58–8.51 (m, 4H), 7.67

mental analysis calculated for $C_{54}H_{58}N_4Q_6 \cdot 1.5H_2O$: C, 73.13; H, 6.88;

N, 6.32. Found: C, 73.02; H, 6.68; N, 6.21.

18H). HRMS (FAB) calculated for $C_{60}H_{68}N_4Q_6 (M^+ + H)$ 935.4748,

18H). HRMS (FAB) calculate **0.5H2O: C, 76.32; H, 6.72; N, 5.93. Found: C, 76.57; H, 7.09; N, 5.65.** *anthracen-9-ylmethyl}-methyl-carbamoyl)-pent-3-*

methyl-carbamic acid tert-butyl ester (6g)
Yield 31%. 'H NMR (CDCla) 8 8.46–8.43 (m. 4H), 8.36–8.32 (m. 4H), *anthracen-9-ylmethyl-amino}-methyl)-anthracen-9-ylmethyl]-*

 $HRMS$ (FAB) calculated for C₆₀H₆₃N₄O₆ (M⁺ + H) 935.4748, found **N, 6.42. Found: C, 71.70; H, 7.03; N, 6.31. 935.4775. Elemental analysis calculated. for C₆₀H₆₂N₄O₆·0.5H₂O: C,**

carbamic acid tert-butyl ester (6h) methyl-amino}-methyl)-anthracen-9-ylmethyl]-methyl-

): 1685, 1643. HRMS (FAB) calculated for C50H59N4O6 5.71 (s, 4H), 5.54 (s, 4H), 2.60 (s, 6H), 2.49 (s, 6H), 2.41 (t, *^J* **7.5** (in $\frac{1}{10}$ -([[7-({10-[(Tert-Butoxycarbonyl-methyl-annino)-methyl-anthracen-9-ylmethyl-methyl-anthracen-9-ylmethyl-methyl-anthracen-9-ylmethyl-methyl-
anthracen-9-ylmethyl-anthracen-9-ylmethyl-anthracen-9-ylmethyl-anth

H NMR (CDCl3) 8.60–8.40 (m, 8H), 7.63–7.55 (m, 8H), Yield 75%. ¹ H NMR (CDCl3) 8.49–8.38 (m, 8H), 7.58–7.55 (m, 8H), (cm⁻¹): 1684, 1635. HRMS (FAB) calculated for $C_{54}H_{59}N_4O_6$ (M⁺ + H)

[10-({[21-({10-[(Tert-Butoxycarbonyl-methyl-amino)- {10-[({4-[4-({10-[(Tert-Butoxycarbonyl-methyl-amino) heneicosanoyl]-methyl-amino}-methyl)-anthracen-9- phenoxy]-benzoyl}-methyl-amino)-methyl]-anthracen-9-

H NMR (CDCl3) 8.60–8.40 (m, 8H), 7.70–7.50 (m, 8H), 5.72 (s, 4H), 5.55 (s, 4H), 2.60 (s, 6H), 2.50 (s, 6H), 2.40–2.34 (m, 4H), 7.49–7.39 (m, 4H), 7.09–6.99 (m, 4H), 5.84 (s, 4H), 5.55 (s, 4H), 2.58): 1692, 1643. HRMS (FAB) calculated (s, 6H), 2.40 (s, 6H), 1.57 (s, 18H). IR (cm¹): 1682, 1632. HRMS (FAB)

Carbarine acid terr-butyr ester (ox)
Yield 74%. ¹H NMR (CDCl₃) δ 8.52–8.45 (m, 8H), 7.60–7.56 (m, 8H), 7.60, 4 .60, 4 .60 (m, 8H), 4 .77 4 .50 (m, 4 .57 .6 (m, 4 .57 .6 .6 .4H), 2.66 (s, 6H), 2.45 (s, 6H), 4.600, 4.60

H NMR (CDCl3) 8.60–8.40 (m, 8H), 7.70–7.50 (m, 8H), *methyl-carbamic acid tert-butyl ester (6l)* **5.77 (s, 4H), 5.56 (s, 4H), 2.70 (s, 6H), 2.55 (s, 6H), 2.56–2.22 (m, 4H), 1.48 (s, 18H), 1.40–1.20 (m, 4H). IR (cm¹ Yield 60%.): 1686, 1637. HRMS (FAB) ¹ H NMR (CDCl3) 8.50–8.31 (m, 8H), 7.62–7.43 (m, 10H),**

[10-({[6-({10-[(Tert-Butoxycarbonyl-methyl-amino)-methyl]- **3.75 (s, 4H), 2.54 (s, 6H), 2.25 (s, 6H). IR (cm¹**

anthracen-9-ylmethyl]-methyl-carbamic acid tert-butyl Diboronic Acid 7c

6H), 1.57 (s, 18H). IR (cm¹ MS-ESI: 494.4 (M 2H)/2.): 1688, 1631. MS-FAB 909.8 (M H). *[10-({[5-({10-[(Tert-Butoxycarbonyl-methyl-amino)-methyl]- Diboronic Acid 7d* **Yield 69%.** *anthracen-9-ylmethyl}-methyl-carbamoyl)-thiophene-2-* **¹ (m, 4H), 7.67–7.65 (m, 2H), 7.55–7.52 (m, 8H), 7.35–7.25 (m, 6H), 7.11** *carbonyl]-methyl-amino}-methyl)-anthracen-9-ylmethyl] methyl-carbamic acid tert-butyl ester (* **(s, 4H), 5.63 (s, 4H), 5.01 (s, 4H), 4.28 (s, 4H), 2.96 (t,** *J* **7.2 Hz,** *6v)*

Yield 55%. ¹H NMR (CDCl₃) δ 8.52–8.49 (m, 4H), 8.39–8.37 (m, 4H), 4H), 4H), 2.54 (t, J = 7.2 Hz, 4H), 2.37
7.61–7.56 (m, 8H), 7.24 (s, 2H), 5.86 (s, 4H), 5.56 (s, 4H), 2.80 (s, 1637. MS-ESI: 492.4 (M⁺ + 2H)/2.
6H), 2

H NMR (CDCl3) 8.64 (s, 2H), 8.55–8.52 (m, 4H), 8.43–8.41 *Diboronic Acid 7f* **(m, 4H), 7.85 (s, 1H), 7.62–7.59 (m, 8H), 5.87 (s, 4H), 5.58 (s, 4H), Yield 32%. ¹** 2.58 (s, 6H), 2.52 (s, 6H), 1.58 (s, 18H). IR (cm⁻¹): 1682, 1632. HRMS
(FAB) calculated for C₅₃H₅₈N₅O₆ (M⁺) 860.4387, found 860.4412.

H NMR (CDCl₃) 8 8.52–8.49 (m, 4H), 8.43–8.40 (m, 4H), **Diboronic Acid** 7g
T.61–7.58 (m, 8H), 5.74 (s, 4H), 5.57 (s, 4H), 2.62 (s, 6H), 2.52 (s, 6H), Yeld 71 %. ¹H NMR (CD₃OD + CDCl₃) 8 8.31–8.28 (m, 4H), 8.18–8. 7.01–7.00 (iii, ori), 0.74 (s, 4H), 0.07 (s, 4H), 2.02 (s, 0H), 2.02 (s, 0H),
2.40 (t, J = 7.2 Hz, 4H), 1.75–1.58 (m, 22H), 1.36–1.29 (m, 20H). IR (m, 4H), 7.56–7.50 (m, 8H), 3.18 (s, 4H), 2.33 (s, 6H), 2.16 (s, 6H).
(cm $\rm (cm^{-1})$: 1688, 1641. HRMS (FAB) calculated for $\rm C_{62}H_{83}N_4O_6$ (M⁺ + H)
979.6313. found 979.6343.

$[10-([10-t] \text{F} - \text{But } 5t^3) \cdot (30-t^2) \cdot (20-t^2) \cdot (20$

5.72 (s, 4H), 5.51 (s, 4H), 2.55 (s, 6H), 2.50 (s, 6H), 2.50-2.44 (m, 4H), 1.90-1.60 (m, 4H), 1.57 (s, 18H).

Yield 33%. ¹H NMR (CDCl₃) d 8.80-8.40 (m, 8H), 8.00-7.40 (m, 14H),

6.10 (s, 4H), 5.65 (s, 4H), 2.60 (s, 6H), 2.40 (s, 6H), 1.60 (s, 18H).

HRMS (FAB) calculated for C₅₈H₆₁N₄O₆ (M⁺ + H) 909.4591, found

909.

): 1649, 1632. MS-ESI: 1113.8 (M 6.65; N, 6.16. Found: C, 76.36; H, 6.72; N, 6.04. H2O H). *General Procedures for Preparation of the Symmetrical Diboronic Acid 7k*

The Boc-protected diamine compound 6 (0.073 mmol) was dissolved in dry CH₂Cl₂ (8mL), then trifluoroacetic acid (3 mL) was
added. After the mixture was stirred at room temperature for 10 **min, the solvent was removed. The residue was dried in vacuo for** *Diboronic Acid 7l* **3** hr and dissolved in dry acetonitrile (30 mL); compound 8 (85 ma, 0.30 mmol), potassium carbonate (100 ma, 0.73 mmol) and **mg, 0.30 mmol), potassium carbonate (100 mg, 0.73 mmol) and (m, 10H), 7.28–7.26 (m, 8H), 7.10–6.90 (m, 2H), 5.89 (s, 2H), 5.76 (s, potassium iodide (2 mg) were then added. The reaction mixture was 2H), 5.16 (s, 2H), 5.12 (s, 2H), 4.90 (s, 2H), 4.38 (s, 2H), 4.35 (s, 2H), stirred at room temperature for 12 hr. The insoluble materials were 2.68 (s, 3H), 2.63 (s, 3H), 2.46 (s, 3H), 2.42 (s, 3H). IR (cm¹): 1632, filtered off, and the filtrate was evaporated in vacuo. The resulting 1608. MS-ESI: 939.5 (M⁺ - H₂O** + H).
 **residue was dissolved in CH₂CI₂ and 10% aqueous solution of so-

Diboronic Acid** 7m residue was dissolved in CH₂Cl₂ and 10% aqueous solution of sodium bicarbonate (20 mL) and the mixture was stirred at room tem**perature for 1 hr. The organic phase was separated and washed 7.74–7.64 (m, 2H), 7.62–7.54 (m, 6H), 7.40–7.20 (m, 8H), 5.68 (s, 4H),** with water (2×30 mL) and dried over MgSO₄. After removal of the **30 mL) and dried over MgSO4. After removal of the 5.06 (s, 4H), 4.37 (s, 4H), 2.58 (s, 6H), 2.50–2.34 (m, 4H), 2.46 (s, 6H),**

Yield 49%. ¹ H NMR (CD3OD) 8.46–8.43 (m, 4H), 8.29–8.24 (m, 4H), Yield 76%. ¹ 7.70–7.67 (m, 2H), 7.59–7.55 (m, 8H), 7.36–7.26 (m, 6H), 5.68 (s, 4H), 4H), 4.70 (s, 4H), 4.35 (s, 4H), 2.25 (s, 12H). ESI-MS: 985.6 (M 5.06 (s, 4H), 4.36 (s, 4H), 2.58 (s, 6H), 2.43–2.38 (m, 4H), 1.64–1.54 (m, H2O H). 4H), 1.36–1.28 (m, 12H). IR (cm¹): 1637. MS-ESI: 496.4 (M 2H)/2. *Diboronic Acid 7o Diboronic Acid 7b*

Yield 81%. ¹H NMR (CD₃OD + CDCl₃) δ 8.40-8.36 (m, 4H), 8.25-8.22 (m, 4H), 7.82–7.18 (m, 20H), 5.69 (s, 4H), 4.89 (s, 4H), 4.08 (s, 4H), 2.62 (s, 6H), 2.40 (s, 6H). ESI-MS: 985.6 (M⁺ - H₂O + H).

): 1637. MS-ESI: 478.4 anthracen-9-ylmethyl}-methyl-carbamoyl)-
 (M⁺ + 2H)/2. Elemental analysis calculated for C₆₀H₆₀B₂N₄O₆·2.4H₂O:

C, 72.21; H, 6.49; N, 5.61. Found: C, 71.96; H, 6.19; N, 5.39. *naphthalene-2-carbonyl]-methyl-amino}-methyl)-* **C, 72.21; H, 6.49; N, 5.61. Found: C, 71.96; H, 6.19; N, 5.39.**

Yield 38%. *ester (6u)* **¹ H NMR (CD3OD CDCl3) 8.32–8.29 (m, 4H), 8.26–8.21 Yield 67%. (m, 4H), 7.80–7.22 (m, 16H), 7.00 (s, 4H), 5.63 (s, 4H), 4.99 (s, 4H), ¹ H NMR (CDCl3) 8.53–8.50 (m, 8H), 7.89–7.86 (m, 4H), 4.78 (s, 4H), 4.33 (s, 4H), 2.40 (s, 6H), 2.37 (s, 6H). IR (cm¹ 7.62–7.51 (m, 10H), 5.91 (s, 4H), 5.56 (s, 4H), 2.59 (s, 6H), 2.51 (s,): 1655.**

H NMR (CD3OD CDCl3) 8.35–8.32 (m, 4H), 8.25–8.22 4H), 2.64 (t, *J* **7.2 Hz, 4H), 2.37 (s, 6H), 2.33 (s, 6H). IR (cm¹): Yield 55%. ¹**

calculated for C₈₂H₅₇N₃O₆S (M⁺ + H) 865.3999, found 865.3973.

(n, 4H), 7.80–7.60 (m, 2H), 7.57–7.54 (m, 8H), 7.36–7.28 (m, 6H), 5.71

(n, 4H), 7.80–7.60 (m, 2H), 7.57–7.54 (m, 8H), 7.36–7.28 (m, 6H), 5.71

anth edisoryly metryl entirely metryl entirely and the contraction of the H₂O + H). Elemental analysis calculated for C₅₅H₅₆B₂N₄O₆·H₂O:

Yield 69%. ¹H NMR (CDCl₃) 8 8.64 (s, 2H), 8.52 (m, 4H), 8.43–8.41 C, 72

 (FAB) calculated for C₅₃H₅₈N₃O₆ (M⁺) 860.4387, found 860.4412. (m, 4H), 7.70–7.59 (m, 10H), 7.39–7.27 (m, 10H), 5.88 (s, 4H), 5.09 (s, 10H) calculated for C₅₃H₅₈N₃O₆ (M⁺) 860.4387, found 860.4412. (m, $[10-([115-([10-([110-([100])-0.0226;H₁₀0.024)]-0.026)]-0.026]$
 $[10-([115-([100-([100])-0.026)]-0.026]$
 $[100-([110-([100])-0.026)]-0.026]$
 $[100-([100]-1.026]$
 $[100-([100]-1.026]$
 $[100-([100]-1.026]$
 $[100-([100]-1.026]$
 $[100-([$

carpamic acid terr-putyl ester (by)
Yield 50%. ¹H NMR (CDCl₃) δ 8.50–8.30 (m, 8H), 7.60–7.40 (m, 8H), (m, 4H), 7.80–7.60 (m, 2H), 7.57–7.54 (m, 8H), 7.36–7.28 (m, 6H), 5.70
E 72 (c 4H), E 51 (c 4H) 3 E (c 6H) 3 E (c 6H 6H). IR (cm⁻¹): 1643, 1632. MS-ESI: 861.5 (M⁺ - H₂O + H).
Diboronic Acid 7i

[10-({[4-({10-[(Tert-Butoxycarbonyl-methyl-amino)-methyl]- **Yield 49%. ¹** anthracen-9-yimethyl-methyl-carbamoyi)-

naphthalene-1-carbonyl]-methyl-amino}-methyl)-

naphthalene-1-carbonyl]-methyl-amino}-methyl)-

anthracen-9-yimethyl-methyl-carbamic

active the state of the carbonyl ester (6z)

a antinacen-s-yimetriyi-metriyi-carbamic
acid tert-butyl ester (6z)
Yield 33%. 'H NMR (CDCl₃) d 8.80-8.40 (m, 8H), 8.00-7.40 (m, 14H), Diboronic Acid 7j
Yield 30%. 'H NMR (CD₃) d 8.80-8.40 (m, 8H), 8.00-7.40 (m, 14H), Yi

Yield 50%. ¹H NMR (CD₃OD + CDCl₃) δ 8.50–8.34 (m, 8H), 7.71–7.61 **The Boc-protected diamine compound 6 (0.073 mmol) was dis- (m, 12H), 7.45–7.34 (m, 8H), 5.86 (s, 4H), 5.06 (s, 4H), 4.24 (s, 4H), 2.57 (s, 6H), 2.42 (s, 6H). IR (cm⁻¹): 1631, 1620. MS-ESI: 909.5 (M⁺
H₂O + H).**

Yield 40%. ¹H NMR (CD₃OD + CDCl₃) δ 8.46–8.30 (m, 8H), 8.29–7.56

H NMR (CD3OD) 8.50–8.38 (m, 4H), 8.32–8.24 (m, 4H), solvent, the crystalline was precipitated from CH₂Cl₂/Et₂O. **1.70–1.48 (m, 4H), 1.40–1.20 (m, 16H). ESI-MS: 1001.7 (M⁺ – H₂O + H).
Diboronic Acid 7n and Diboronic Acid 7n and The Cold Transic Acid 7n** *Diboronic Acid 7a Diboronic Acid 7n*

Yield 76%. ¹H NMR (CD₃OD + CDCl₃) δ 8.45–7.10 (m, 32H), 5.80 (s,

Yield 89%. ¹H NMR (CD₃OD + CDCl₃) δ 8.60–8.50 (m, 4H), 8.40–8.24 **H NMR (CD3OD CDCl3) 8.40–8.36 (m, 4H), 8.25–8.22 (m, 4H), 7.90–7.20 (m, 24H), 5.90 (s, 4H), 4.94 (s, 4H), 4.20 (s, 4H),**

Yield 78%. ¹H NMR (CD₃OD + CDCl₃) δ 8.50–8.36 (m, 4H), 8.32–8.16 $\hskip 1cm \hskip 1cm \hskip$ **(m, 4H), 7.74–7.44 (m, 10H), 7.42–7.20 (m, 6H), 5.64 (s, 4H), 4.99 (s, at 1:500. Cells were then stained with fluorescein isothiocyanate-4H), 4.35 (s, 4H), 2.42–2.30 (m, 4H), 2.41 (s, 6H), 2.37 (s, 6H), 1.70–1.54 conjugated goat anti-mouse IgM or anti-mouse IgG. FITC-conju- (m, 4H), 1.46–1.32 (m, 2H). IR (cm¹**

Yield 70%. previously described (13, 14). ¹ H NMR (CD3OD) 8.60–8.40 (m, 4H), 8.32–8.20 (m, 4H), 7.72–7.52 (m, 12H), 7.50–7.20 (m, 8H), 5.81 (s, 4H), 5.06 (s, 4H), 4.34 *Fluorescent Labeling Studies* (s, 4H), 2.47 (s, 6H), 2.39 (s, 6H). IR (cm⁻¹): 1626. MS-ESI: 969.5 Six-well plates were seeded with 1 \times 10⁶ cells per well and incubated $(M^+ + 3$ MeOH $- 3H_2O + H$). Elemental analysis calculated for **C58H56B2N4O6·2H2O: C, 72.28; H, 6.07; N, 5.82. Found: C, 72.27; H, were washed twice with 1**-

Yield 65%. ¹H NMR (CD $_{3}$ **OD)** δ 8.60–8.42 (m, 4H), 8.40–8.30 (m, 4H), twice with PBS. **7.80–7.52 (m, 10H), 7.50–7.20 (m, 10H), 7.15–7.00 (m, 4H), 5.81 (s, Diboronic acid compounds were resuspended in 1:1 methanol/ 4H), 5.04 (s, 4H), 4.35 (s, 4H), 2.54 (s, 6H), 2.40 (s, 6H). IR (cm¹ 1616. MS-ESI: 1029.5 (M⁺ + 2MeOH–3H₂O + H). incubated only in methanol/PBS without compound as a negative**

Yield 58%. ¹H NMR (CD₃OD) δ 8.55–8.50 (m, 4H), 8.40–8.25 (m, 4H), 7.72–7.52 (m, 8H), 7.44–7.20 (m, 8H), 5.16 (s, 4H), 4.40 **2H), 1.70–1.56 (m, 2H). IR (cm¹**

Yield 70%. toshop 6.0. The images were quantified with NIH ImageJ 1.28. The ¹ H NMR (CD3OD) 8.50–8.40 (m, 4H), 8.38–8.24 (m, 4H), 7.76–7.52 (m, 10H), 7.40–7.24 (m, 6H), 5.70 (s, 4H), 5.10 (s, 4H), 4.40 units (mean gray value) were subtracted from background, where (s, 4H), 2.80–2.62 (m, 2H), 2.66 (s, 6H), 2.44 (s, 6H), 1.90–1.74 (m, there are no cells. The fluorescent signal was stable for at least 96 2H), 1.70–1.60 (m, 2H). IR (cm¹ 2MeOH 2H2O). Elemental analysis calculated for C58H62B2N4O6· *Neuraminidase and Fucosidase Studies* **3H2O: C, 70.59; H, 6.95; N, 5.82. Found C, 70.56; H, 6.35; N, 5.81. HEPG2 cells (sLex-expressing) were treated with neuraminidases**

Yield 31%. ¹H NMR (CD₃OD + CDCl₃) δ 8.68-8.50 (m, 4H), 8.33-8.31 **(cm¹): 1613. MS-ESI: 959.4 (M H2O H). Tris-HCL (pH 7.5) 25 mM NaCl (5**-

<code>Yield 49%.1H</code> <code>NMR (CD $_3$ OD</code> $+$ CDCl $_3$) δ 8.42–8.40 (m, 4H), 8.29–8.26 treated with buffer alone at the same conditions. Incubation of cells **4H), 5.02 (s, 4H), 4.31 (s, 4H), 2.76 (s, 6H), 2.39 (s, 6H). IR (cm number MFCD00130491, SIGMA #F3023) were performed using the ¹):**

Yield 65%. ¹H NMR (CD₃OD + CDCl₃) δ 8.53-8.49 (m, 4H), 8.33-8.31 **4H), 4.33 (s, 4H), 2.56 (s, 6H), 2.41 (s, 6H). IR (cm¹ 910.4** ($M^+ - H_2O + H$). **photographed as above.**

Diboronic Acid 7x

Yield 45%. ¹H NMR (CD₃OD + CDCl₃) δ 8.44-8.40 (m, 4H), 8.32-8.22 **H NMR (CD3OD CDCl3) 8.44–8.40 (m, 4H), 8.32–8.22 Acknowledgments (m, 4H), 7.78–7.64 (m, 2H), 7.58–7.56 (m, 8H), 7.37–7.28 (m, 6H), 5.69 (s, 4H), 5.08 (s, 4H), 4.31 (s, 4H), 2.60 (s, 6H), 2.44–2.37 (m, 10H), We gratefully acknowledge the financial support from the National 1.80–1.60 (m, 4H), 1.35–1.27 (m, 20H). IR (cm¹**

H NMR (CD3OD CDCl3) 8.40–7.40 (m, 24H), 5.63 (s, experiments. 4H), 4.70 (s, 4H), 4.10 (s, 4H), 2.56 (s, 6H), 2.47 (t, *^J* **7.0 Hz, 4H),** 2.30 (s, 6H), 1.99-1.60 (m, 4H). ESI-MS: 889.6 (M⁺ - H₂O + H). Elemental analysis calculated. for C₅₆H₆₀B₂N₄O₆, C, 74.18; H, 6.67; N, **References 6.18. Found C, 74.55; H, 7.00; N, 5.75.**

(m, 4H), 8.00–7.20 (m, 22H), 6.10-5.74 (m, 4H), 4.80 (s, 4H), 4.19 (s, μ), Eukuda, M. (1994). Cell surface carbohydrates: Cell-type spe-
4H), 2.36 (s, 6H), 2.29 (s, 6H). ESI-MS: 959.5 (M⁺ $-$ H₂O + H). entic expres

HEPG2 and COS7 cells were maintained in RPMI with 10% FBS drates and Cell Development, M. Fukuda, ed. (Boca Raton: (GIBCO). HEP3B cells were maintained in RPMI with 10% FBS and CRC), pp 127–160. 1 \times sodium pyruvate and 1 \times

Cell lines HEPG2, HEP3B, and COS7 were prepared and stained with monoclonal anti-carbohydrate antibodies at saturating concen-

Raton: CRC), pp. 161-194. **trations as described (13, 14). Anti-SSEA-1 (anti-Lewis X) was used 5. Jorgensen, T., Berner, A., Kaalhus, O., Tveter, K.J., Danielsen, at a dilution of 1:1000, anti-Lewis Y (clone F3, Calbiochem, and H.E., and Bryne, M. (1995). Up-regulation of the oligosaccharide**

Diboronic Acid 7p **clone A70-C/C8, NeoMarkers) at a dilution of 1:20, anti-sialyl Lewis** gated murine IgG1/IgG2 and anti-CD18 antibodies (negative con-**2MeOH** $-$ 2H₂O + H). \blacksquare *Diboronic Acid 7q* **tions. Cells were analyzed on a Becton-Dickinson FACScan as**

Six-well plates were seeded with 1×10^6 cells per well and incubated **C and 5% CO2 for 48 hr. The media was removed and cells** were washed twice with $1 \times$ PBS. The cells were fixed with 1.5 ml **6.05; N, 5.87. of 1:1 methanol/PBS and incubated 20 min at 4 C. After incubation,** *Diboronic Acid 7r* **the methanol/PBS solution was removed and cells were washed**

): PBS and added to wells at 0.5–10 M concentrations. One well was *Diboronic Acid 7s* **control. The plates were then incubated in darkness at 4 C for 45 Yield 58%. min. Plates were examined with phase contrast microscopy followed ¹** by fluorescent microscopy (blue cube wavelengths 370 nm excita-**(s, 4H), 2.86–2.78 (m, 2H), 2.64 (s, 6H), 2.47 (s, 6H), 2.20–2.08 (m, tion, 426 nm emission; 20X lens). Plates were photographed using** a Nikon DXM1200 digital camera and images captured with the Nikon ACT-1 program (v 2.10). The phase contrast and fluorescent *Diboronic Acid 7t* **images were then overlaid, organized and labeled using Adobe Pho-): 1634. MS-ESI: 960.4 (M hr when cells were maintained in darkness.**

Diboronic Acid 7u **specific for (2,3) sialic acid linkages (MDL number MFCD01092203,** $H(MA H V 271)$ and α (2,3)/ α (2,6) sialic acid residues (MDL number **(m, 4H), 7.92–7.90 (m, 4H), 7.65–7.62 (m, 12H), 7.34–7.20 (m, 6H), MFCD01092201, SIGMA #N5521) according to modifications of 5.93 (s, 4H), 5.10 (s, 4H), 4.35 (s, 4H), 2.59 (s, 6H), 2.43 (s, 6H). IR manufacturer's protocols. Incubations were performed in 20 mM** Tris-HCL (pH 7.5) 25 mM NaCl (5× reaction buffer is 250 mM sodium *Diboronic Acid 7v* **phosphate [pH 6.0]) at 37 C for four hours. Control HEPG2 were (m, 4H), 7.69 (m, 2H), 7.60–7.55 (m, 8H), 7.37–7.25 (m, 8H), 5.82 (s, with fucosidase recognizing (1,3)- and (1,4) –linked fucose (MDL 1614. MS-ESI: 915.4 (M**⁺ $-H_2O + H$). Same buffers and conditions except the phosphate buffer is at pH **Diboronic Acid** *7w* **5.0. Incubation with both** α (1,3/1,4)fucosidase (F3023) and α (2,3)neuraminidase (N7271) were performed with the same buffers **(m, 4H), 7.68–7.60 (m, 10H), 7.37–7.22 (m, 9H), 5.84 (s, 4H), 5.07 (s, and conditions except the pH was 5.5. The cells were then stained): 1631. MS-ESI: with 7q and controls, examined under fluorescent microscopy, and**

1029.6 (M⁺ – H₂O + H).

Diboronic Acid 7y

Diboronic Acid 7y

Yield 91%. ¹H NMR (CD₃OD + CDCl₃) δ 8.40–7.40 (m, 24H), 5.63 (s,

Wish to thank Bihui Zeng for expert assistance with cell labeling

4H) 4.70 (s,

- **Diboronic Acid** 7z

Yield 98%. ¹H NMR (CD₃OD + CDCl₃) 6 8.66-8.58 (m, 4H), 8.24-8.08

opment. (Boca Raton: CRC).
	- **Hindsgaul, eds. (New York: Oxford University), pp. 1–52.**
- **Biology 3. Fukuda, M. (1992). Cell surface carbohydrates in hematopoietic** *Cell Culture* **cell differentiation and malignancy.** In Cell Surface Carbohy-
- **nonessential amino acids (GIBCO). 4. Dennis, J.W. (1992). Changes in glycosylation associated with** *Flow Cytometry Analysis* **malignant transformation and tumor progression. In Cell Surface**
	-

tate cancer. Cancer Res. 55, 1817–1819.
6. Idikio, H.A. (1997). Sialyl Lewis X, gleason grade and stage in 27. Wiskur, S.L., and Anslyn, E.V. (2001). Using a synthetic reception-enhanced quenching. Tetrahedron Lett. 40, 78

-
- **7. El-Serag, H.B., and Mason, A.C. (1999). Rising incidence of he- A colorimetric assay for the aging of scotch. J. Am. Chem. Soc. patocellular carcinoma in the United States. N. Engl. J. Med.** *123***, 10109–10110.**
-
- **9. Yago, K., Zenita, K., Ginya, H., Sawada, M., Ohmori, K., Minoru, in water. Anal. Chem.** *73***, 1530–1536. O., Kannagi, R., and Lowe, J. (1993). Expression of alpha(1,3)- 29. Yang, W., He, H., and Drueckhammer, D.G. (2001). Computermalignant cell lines. Cancer Res.** *53***, 5559–5565. 1714–1718.**
- **aminoisobutyric acid uptake in HEPG2 cells. Int. J. Biochem. 31. Ward, C.J., Patel, P., and James, T.D. (2002). Molecular color**
- **Cell Biol..** *29***, 667–674. sensors for monosaccharides. Org. Lett.** *4***, 477–479. production in two hepatoma cell lines. J. Immunol.** *146***, 3032– 33. Wang, W., Gao, S., and Wang, B. (1999). Building fluorescent**
- **12. Minta, J.O., Fung, M., and Paramasawara, B. (1998). Transcrip- rescent sensor for D-fructose. Org. Lett.** *1***, 1209–1212. Biophys. Acta** *1442***, 286–295. tions. Bioorg. Chem.** *29***, 308–320.**
- **troenterol.** *29***, 24–30. allosterism. J. Am. Chem. Soc.** *123***, 10239–10244.**
- **14. Brinkman-Van der Linden, E.C.M., Mollicone, R., Oriol, R., Lar- 36. Wulff, G. (1982). Selective binding to polymers via covalent sense mutation in the FUT6 gene results in total absense of sites. Pure Appl. Chem.** *54***, 2093–2102. alpha3-fucosylation of human alpha1-acid glycoprotein. J. Biol. 37. Karnati, V.R., Gao, X., Gao, S., Yang, W., Ni, W., Sankar, S., and**
- **fucosyltransferase activity in patients with hepatocellular carci- 3373–3377. noma, with special reference to correlation with fucosylated 38. Lin, Y.-I., Lang, S.A., Seifert, C.M., Child, R.G., Morton, G.O.,**
- **K., and Sugimachi, K. (2002). The sialyl Lewis X expression in 4701–4703. hepatocarcinogenesis: potential predictor for the emergence of 39. Okada, Y., Jin-no, K., Ikeda, H., Sakai, N., Sotozono, M., Yonei,**
-
- **18. Yang, W., Gao, S., Gao, X., Karnati, V., Ni, W., Wang, B., Hooks, carcinomas. Cancer** *73***, 1811–1816. Med. Chem. Lett.** *12***, 2175–2177. hepatobiliary diseases. Liver** *12***, 140–146.**
- **19. Weston, B.W., Hiller, K.M., Mayben, J.P., Manousos, G.A., 41. Sasaki, M., Kono, N., and Nakanuma, Y. (1994). Neoexpression** Bendt, K.M., Liu, R., and Cusack, J.C., Jr. (1999). Expression of **human a(1,3)fucosyltransferase antisense sequences inhibits damaged intrahepatic bile ducts. Hepatology** *19***, 138–144. selectin-mediated adhesion and liver metastasis of colon carci- 42. Hiller, K.M., Mayben, J.P., Bendt, K.M., Manousos, G.A., Singer,**
-
- **21. Wang, W., Gao, X., and Wang, B. (2002). Boronic acid-based cells. Mol. Carcinog.** *27***, 280–288.** sensors for carbohydrates. Curr. Org. Chem. 6, 1285-1317.
- **346–368. alpha(1,3/1,4)fucosyltransferase. J. Biol. Chem.** *267***, 4152–4160.**
- **23. James, T.D., Sandanayake, K.R.A.S., Iguchi, R., and Shinkai, S. 44. Weston, B.W., Smith, P.L., Kelly, R.J., and Lowe, J.B. (1992). cosyltransferase gene family. J. Biol. Chem.** *267***, 24575–24584. sors based on the interaction of boronic acid and amine. J. Am. Chem. Soc.** *117***, 8982–8987.**
- **24. James, T.D., Sandanayake, K.R.A.S., and Shinkai, S. (1995). Chiral discrimination of monosacchrides using a fluorescent molecular sensor. Nature** *374***, 345–347.**
- **25. Eggert, H., Frederiksen, J., Morin, C., and Norrild, J.C. (1999). A new glucose-selective fluorescent bisboronic acid. First report of strong a-furanose complecation in aqueous solution at physiological pH. J. Org. Chem.** *64***, 3846–3852.**
- **26. Adhikiri, D.P., and Heagy, M.D. (1999). Fluorescent chemo-**

sialyl Lewis X: A new prognostic parameter in metastatic pros-
sensor for carbohydrates which shows large change in chela-

- **6. Idikio, H.A. (1997). Sialyl Lewis X, gleason grade and stage in 27. Wiskur, S.L., and Anslyn, E.V. (2001). Using a synthetic receptor nonmetastatic human prostate cancer. Glycoconj. J.** *14***, 875–877. to create an optical-sensing ensemble for a class of analytes:**
- *340***, 745–750. 28. Tong, A.-J., Yamauchi, A., Hayashita, T., Zhang, Z.-Y., Smith, 8. Shacter, E., and Weitzman, S.A. (2002). Chronic inflammation B.D., and Teramae, N. (2001). Boronic acid fluorophore/betaand cancer. Oncology** *16***, 217–223. cyclodextrin complex sensors for selective sugar recognition**
	- **fucosyltransferases which synthesize sialyl Le(x) and sialyl guided design in molecular recognition: Design and synthesis Le(a), the carbohydrate ligands for E- and P-selectins in human of a glucopyranose receptor. Angew. Chem. Int. Ed. Engl.** *40***,**
- **10. Goenner, S., Cosson, C., Boutron, A., Legrand, A., and Moatti, 30. DiCesare, N., and Lakowicz, J.R. (2001). New color chemosensors N. (1997). Interleukin-1 and interleukin-6 stimulate 2-methyl- for monosaccharides based on azo dyes. Org. Lett.** *3***, 3891–3893.**
	-
	- **11. Mackiewicz, A., Speroff, T., Ganapathi, M.K., and Kushner, I. 32. Springsteen, G., and Wang, B. (2002). A detailed examination (1991). Effects of cytokine combinations on acute phase protein of boronic acid-diol complexation. Tetrahedron** *58***, 5291–5300.**
	- **3037. sensors by template polymerization: the preparation of a fluo-**
	- **tional and post-transcriptional regulation of complement factor 34. Gao, S., Wang, W., and Wang, B. (2001). Building fluorescent I (CFI) gene expression in HEPG2 cells by interleukin-6. Biochim. sensors for carbohydrates using template-directed polymeriza-**
- **13. Nakaya, R., Kohgo, Y., Mogi, Y., Kakajima, M., Kato, J., and 35. Sugasaki, A., Sugiyasu, K., Ikeda, M., Takeuchi, M., and Shinkai, Niitsu, Y. (1994). Regulation of asialoglycoprotein receptor syn- S. (2001). First successful molecular design of an artificial Lewis thesis by inflammation-related cytokines in HEPG2 cells. J. Gas- oligosaccharide binding system utilizing positive homotropic**
	- **son, G., Van der Eijnden, D.H., and Van Dijk, W. (1996). A mis- bonds–The construction of chiral cavities as specific receptor-**
- **Chem.** *271***, 14492–14495. Wang, B. (2002). A glucose-selective fluorescence sensor based 15. Mita, Y., Aoyagi, Y., Suda, T., and Asakura, H. (2000). Plasma on boronic acid-diol recognition. Bioorg. Med. Chem. Lett.** *12***,**
- **species of alpha-fetoprotein. J. Hepatol.** *32***, 946–954. and Fabio, P.F. (1979). Aldehyde syntheses. Study of the prepa-16. Fujiwara, Y., Shimada, M., Takenaka, K., Kajiyama, K., Shirabe, ration of 9,10-anthracenedicarboaldehyde. J. Org. Chem.** *44***,**
- **hepatocellular carcinoma. Hepatogastroenterology** *49***, 213–217. T., Nakanishi, S., Moriwaki, S., and Tsuji, T. (1994). Changes in** 17. Nakakura, E.K., and Choti, M.A. (2000). Management of hepato-
 the expression of sialyl-Lewis^x, a hepatic necroinflammation**cellular carcinoma. Oncology** *14***, 1085–1098. associated carbohydrate neoantigen, in human hepatocellular**
	- **W.B., Carson, J., and Weston, B. (2002). Diboronic acids as 40. Jezequel-Cuer, M., Dalix, A.M., Flejou, J.F., and Durand, G. fluorescent probes for cells expressing sialyl Lewis X. Bioorg. (1992). Variations in human liver fucosyltransferase activities in**
		-
- **noma cells. Cancer Res.** *59***, 2127–2135. K., Cameron, H.S., and Weston, B.W. (2000). Transfection of 20. Lorand, J.P., and Edwards, J.O. (1959). Polyol complexes and alpha(1,3)fucosyltransferase antisense sequences impairs the structure of the benzeneboronate ion. J. Org. Chem.** *24***, 769–774. proliferative and tumorigenic ability of human colon carcinoma**
- **22. Yang, W., Gao, X., and Wang, B. (2003). Boronic acid com- Isolation of a novel human alpha(1,3)fucosyltransferase gene pounds as potential pharmaceutical agents. Med. Res. Rev.** *23***, and molecular comparison to the human Lewis blood group**
	- **Molecular cloning of a fourth member of a human alpha(1,3)fu- (1995). Novel saccharide-photoinduced electron transfer sen-**